Reaction

Depersonalisation/Derealisation Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,589 reports · 45 co-occurring drugs

As of the last recalculation, Depersonalisation/Derealisation Disorder appears in 1,589 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is PAROXETINE HYDROCHLORIDE HEMIHYDRATE (PRR 35.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Paroxetine Hydrochloride Hemihydrate	85	35.3	35.3
Paroxetine	85	34.5	34.6
Mirtazapine	135	21.0	21.0
Dutasteride	12	19.5	19.5
Sertraline	139	16.9	16.9
Paroxetine Hydrochloride	106	16.3	16.3
Mesna Injection	10	15.9	16.0
Mesna	10	15.7	15.7
Amitriptyline Hydrochloride	19	14.3	14.4
Quetiapine Fumarate	31	14.0	14.0
Diazepam Oral Solution (Concentrate)	89	13.8	13.8
Diazepam Oral	89	13.8	13.8
Ciprofolxacin	72	13.7	13.8
Ciprofloxacin Tablets	72	13.7	13.8
Fluoxetine	62	12.6	12.6
Minocycline	11	12.4	12.4
Ciprofloxacin	82	12.3	12.3
Finasteride	54	12.1	12.1
Ciprofloxacin Hydrochloride	85	12.0	12.0
Elexacaftor, Tezacaftor, And Ivacaftor	11	11.6	11.6
Clonazepam	131	11.6	11.6
Diazepam	101	11.5	11.6
Tramadol Hydrochloride	32	11.3	11.4
Fluoxetine Hydrochloride	99	10.8	10.8
Pegaspargase	10	10.8	10.8
Lurasidone Hydrochloride	17	10.7	10.8
Quetiapine	143	10.6	10.6
Metronidazole Topical	37	10.4	10.4
Venlafaxine	55	10.4	10.4
Esketamine Hydrochloride	14	10.4	10.4
Clarithromycin	25	9.7	9.7
Escitalopram Oxalate	52	9.6	9.6
Propranolol Hydrochloride	49	9.2	9.2
Methylphenidate	20	9.2	9.2
Methylphenidate Hydrochloride	39	8.8	8.8
Escitslopram	38	8.7	8.7
Lisdexamfetamine Dimesylate	19	7.6	7.6
Brexpiprazole	9	7.1	7.1
Desvenlafaxine Succinate	14	6.8	6.8
Fremanezumab-Vfrm	5	5.7	5.7
Vortioxetine	6	4.6	4.6
Brivaracetam	3	4.4	4.4
Isotretinoin	12	3.2	3.2
Minoxidil Foam 5% (Womens)	8	3.2	3.2
Minoxidil	8	2.3	2.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.